A
Alison Langley
Researcher at Ipsen
Publications - 14
Citations - 1573
Alison Langley is an academic researcher from Ipsen. The author has contributed to research in topics: Lanreotide & Neuroendocrine tumors. The author has an hindex of 5, co-authored 14 publications receiving 1269 citations.
Papers
More filters
Journal ArticleDOI
Lanreotide in metastatic enteropancreatic neuroendocrine tumors.
Martyn Caplin,Marianne Pavel,Jarosław B. Ćwikła,Alexandria T. Phan,Markus Raderer,Eva Sedlackova,Guillaume Cadiot,Edward M. Wolin,Jaume Capdevila,Lucy Wall,Guido Rindi,Alison Langley,Séverine Martinez,Joëlle Blumberg,Philippe Ruszniewski +14 more
TL;DR: Lanreotide was associated with significantly prolonged progression-free survival among patients with metastatic enteropancreatic neuroendocrine tumors of grade 1 or 2 (Ki-67 <10%) and the therapeutic effect in predefined subgroups was generally consistent with that in the overall population.
Journal ArticleDOI
Anti-tumour effects of lanreotide for pancreatic and intestinal neuroendocrine tumours: The CLARINET open-label extension study
Martyn Caplin,Marianne Pavel,Jarosław B. Ćwikła,Alexandria T. Phan,Markus Raderer,Eva Sedlackova,Guillaume Cadiot,Edward M. Wolin,Jaume Capdevila,Lucy Wall,Guido Rindi,Alison Langley,Séverine Martinez,Edda Gomez-Panzani,Philippe Ruszniewski +14 more
TL;DR: This OLE study suggests long-term treatment with lanreotide Autogel 120 mg maintained favourable safety/tolerability, and provides new evidence of Lanreotide anti-tumour benefits in indolent and progressive pancreatic/intestinal NETs.
Journal ArticleDOI
Tumor growth rate as a metric of progression, response, and prognosis in pancreatic and intestinal neuroendocrine tumors.
Clarisse Dromain,Marianne Pavel,Philippe Ruszniewski,Alison Langley,Christine Massien,Eric Baudin,Martyn Caplin +6 more
TL;DR: TGR provides valuable information on tumor activity and prognosis in patients with metastatic intestinal/pancreatic NETs, and identifies early lanreotide depot/autogel antitumor activity.
Journal ArticleDOI
Progression-free survival (PFS) with lanreotide autogel/depot (LAN) in enteropancreatic NETs patients: The CLARINET extension study.
Martyn Caplin,Philippe Ruszniewski,Marianne Pavel,Jarosław B. Ćwikła,Alexandria T. Phan,Markus Raderer,Eva Sedlackova,Guillaume Cadiot,Lucy Wall,Guido Rindi,Alison Langley,Joëlle Blumberg +11 more
TL;DR: The CLARINET core study showed that the long-acting somatostatin analog (SSA) LAN 120 mg significantly prolonged PFS vs placebo (PBO) in patients with metastatic enteropancr...
Journal ArticleDOI
Lanreotide depot/autogel (LAN) in patients with neuroendocrine tumors (NETs) aged 65 years: Subgroup analyses from the CLARINET study.
Arvind Dasari,Alexandria T. Phan,Martyn Caplin,Marianne Pavel,Jarosław B. Ćwikła,Markus Raderer,Eva Sedlackova,Guillaume Cadiot,Edward M. Wolin,Jaume Capdevila,Lucy Wall,Guido Rindi,Alison Langley,Edda Gomez-Panzani,Philippe Ruszniewski +14 more
TL;DR: The somatostatin analog LAN 120 mg significantly prolonged progression-free survival (PFS) vs. placebo (PBO) in patients with metastatic grade 1 or 2 (Ki-67 <10%) nonfunctioning chemotherapy patients.